ADC Therapeutics Announces Plan to Discontinue the Phase 2 LOTIS-9 Clinical Trial of…
LAUSANNE, Switzerland, July 20, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that it plans to discontinue the Phase 2 LOTIS-9 clinical trial evaluating…